NYSEARCA:IHE iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News $111.08 +0.62 (+0.56%) Closing price 04:10 PM EasternExtended Trading$110.98 -0.10 (-0.09%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest About iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IHE alerts:Sign Up Key Stats Today's Range$109.50▼$111.1350-Day Range$97.36▼$110.4652-Week Range$79.82▼$111.13Volume258,091 shsAverage Volume178,103 shsMarket Capitalization$1.69 billionAssets Under Management$1.72 billionDividend Yield1.29%Net Expense Ratio0.38%Aggregate RatingModerate Buy ETF Overview iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors. Read More iShares U.S. Pharmaceuticals ETF ExpensesTypeIHEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.38%0.55%0.57%0.50%0.53%Other Expenses0.00%0.52%0.53%0.60%0.54%Total Expense0.38%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.76%-0.67%Net Expense0.38%0.58%0.63%0.57%0.60% Receive IHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IHE ETF News HeadlinesWhich Is the Better Buy: iShares' Pharma ETF IHE or First Trust's Biotech Fund FBT?39 minutes ago | fool.comWhich Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?October 26, 2026 | finance.yahoo.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?October 11, 2026 | fool.comBetter Pharma ETF: iShares IHE vs. State Street XPHOctober 10, 2026 | fool.comIHE: Innovation Supports The Outlook, Valuation Limits ConvictionSeptember 11, 2026 | seekingalpha.comSee More Headlines IHE ETF - Frequently Asked Questions How have IHE shares performed this year? iShares U.S. Pharmaceuticals ETF's stock was trading at $84.83 on January 1st, 2026. Since then, IHE shares have increased by 30.5% and is now trading at $110.7270. When did iShares U.S. Pharmaceuticals ETF's stock split? Shares of iShares U.S. Pharmaceuticals ETF split before market open on Thursday, March 7th 2024.The 3-1 split was announced on Thursday, March 7th 2024. The newly issued shares were distributed to shareholders after the market closes on Thursday, March 7th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares U.S. Pharmaceuticals ETF's major shareholders? Top institutional investors of iShares U.S. Pharmaceuticals ETF include Fisher Asset Management LLC (17.97%), MinichMacGregor Wealth Management LLC (2.06%), McElhenny Sheffield Capital Management LLC (0.87%) and Virtue Capital Management LLC (0.41%). How do I buy shares of iShares U.S. Pharmaceuticals ETF? Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares U.S. Pharmaceuticals ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Micron Technology (MU), JPMorgan Chase & Co. (JPM), Coca-Cola (KO), Eli Lilly and Company (LLY) and Visa (V). Fund Details IssueriShares Fund NameiShares U.S. Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IHE Inception Date5/1/2006 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason Webwww.iShares.com PhoneN/AFund Focus Asset ClassEquity BenchmarkDow Jones U.S. Select Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings56 Fund Statistics Assets Under Management$1.72 billion Average Daily Volume$283.84 thousand Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorCitibank, N.A. AdvisorBlackRock Fund Advisors CustodianCitibank, N.A. DistributorBlackRock Investments, LLC Transfer AgentCitibank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume2 Put Options0 Call Options2 Short Interest429,057 shs Miscellaneous Outstanding Shares15,200,000Beta0.47 Creation Unit50,000 Creation Fee$306.00 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report Top 10 IHE HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 26.88%Johnson & Johnson (NYSE:JNJ)Holding Weight: 21.80%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.73%Pfizer (NYSE:PFE)Holding Weight: 4.68%Zoetis (NYSE:ZTS)Holding Weight: 4.64%Viatris (NASDAQ:VTRS)Holding Weight: 4.56%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 4.32%Bristol Myers Squibb (NYSE:BMY)Holding Weight: 4.14%Jazz Pharmaceuticals (NASDAQ:JAZZ)Holding Weight: 2.93%Elanco Animal Health (NYSE:ELAN)Holding Weight: 2.41%Full Holdings DetailsIHE Sector ExposureIHE Industry Exposure This page (NYSEARCA:IHE) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersHas The AI Bubble Popped?A recent sell-off wiped $2.3 trillion off the Nasdaq 100 in a single day, leaving Wall Street split on whether...Porter & Company | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares U.S. Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares U.S. Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
